Research and analysis of differential gene expression in CD34 hematopoietic stem cells in myelodysplastic syndromes

被引:0
|
作者
Wang, Min-xiao [1 ,2 ,3 ]
Liao, Chang-sheng [2 ,4 ]
Wei, Xue-qin [1 ,2 ]
Xie, Yu-qin [1 ,2 ]
Han, Peng-fei [4 ]
Yu, Yan-hui [1 ,3 ]
机构
[1] Changzhi Med Coll, Heping Hosp, Dept Hematol, Changzhi, Shanxi, Peoples R China
[2] Changzhi Med Coll, Grad Student Dept, Dept Grad Sch, Changzhi, Shanxi, Peoples R China
[3] Changzhi Med Coll, Stem Cell & Tissue Engn Res Ctr, Changzhi 046000, Shanxi, Peoples R China
[4] Changzhi Med Coll, Heping Hosp, Dept Orthoped, Changzhi, Shanxi, Peoples R China
来源
PLOS ONE | 2025年 / 20卷 / 03期
基金
中国国家自然科学基金;
关键词
REGULATORY FACTOR 4; IRF4; LEUKEMIA; ELANE;
D O I
10.1371/journal.pone.0315408
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective This study aims to investigate and analyze the differentially expressed genes (DEGs) in CD34 + hematopoietic stem cells (HSCs) from patients with myelodysplastic syndromes (MDS) through bioinformatics analysis, with the ultimate goal of uncovering the potential molecular mechanisms underlying pathogenesis of MDS. The findings of this study are expected to provide novel insights into clinical treatment strategies for MDS.Methods Initially, we downloaded three datasets, GSE81173, GSE4619, and GSE58831, from the public Gene Expression Omnibus (GEO) database as our training sets, and selected the GSE19429 dataset as the validation set. To ensure data consistency and comparability, we standardized the training sets and removed batch effects using the ComBat algorithm, thereby integrating them into a unified gene expression dataset. Subsequently, we conducted differential expression analysis to identify genes with significant changes in expression levels across different disease states. In order to enhance prediction accuracy, we incorporated six common predictive models and trained them based on the filtered differential gene expression dataset. After comprehensive evaluation, we ultimately selected three algorithms-Lasso regression, random forest, and support vector machine (SVM)-as our core predictive models. To more precisely pinpoint genes closely related to disease characteristics, we utilized the aforementioned three machine learning methods for prediction and took the intersection of these prediction results, yielding a more robust list of genes associated with disease features. Following this, we conducted in-depth analysis of these key genes in the training set and validated the results independently using the GSE19429 dataset. Furthermore, we performed differential analysis of gene groups, co-expression analysis, and enrichment analysis to delve deeper into the mechanisms underlying the roles of these genes in disease initiation and progression. Through these analyses, we aim to provide new insights and foundations for disease diagnosis and treatment. Figure illustrates the data preprocessing and analysis workflow of this study.Results Our analysis of differentially expressed genes (DEGs) in CD34+ hematopoietic stem cells (HSCs) from patients with myelodysplastic syndromes (MDS) revealed significant differences in gene expression patterns compared to the control group (individuals without MDS). Specifically, the expression levels of two key genes, IRF4 and ELANE, were notably downregulated in CD34+ HSCs of MDS patients, indicating their downregulatory roles in the pathological process of MDSConclusion This study sheds light on the potential molecular mechanisms underlying MDS, with a particular focus on the pivotal roles of IRF4 and ELANE as key pathogenic genes. Our findings provide a novel perspective for understanding the complexity of MDS and exploring therapeutic strategies. They may also guide the development of precise and effective treatments, such as targeted interventions directed against these genes
引用
收藏
页数:27
相关论文
共 50 条
  • [41] CD34 expression by murine hematopoietic stem cells mobilized by granulocyte colony-stimulating factor
    Tajima, F
    Sato, T
    Lever, JH
    Ogawa, M
    BLOOD, 2000, 96 (05) : 1989 - 1993
  • [42] The expression of the hematopoietic stem cell antigen CD34 is reduced by retinoic acid in neuroblastoma cells.
    Häfer, R
    Voigt, A
    Gruhn, B
    Glaser, D
    Becker, S
    Lorenz, I
    Zintl, F
    BLOOD, 2000, 96 (11) : 186A - 186A
  • [43] Expression of the hematopoietic markers CD34 and c-kit in human liver epithelial stem cells
    Crosby, HA
    Hubscher, SG
    Kelly, DA
    Strain, AJ
    HEPATOLOGY, 1999, 30 (04) : 307A - 307A
  • [44] CHARACTERIZATION OF MURINE CD34, A MARKER FOR HEMATOPOIETIC PROGENITOR AND STEM-CELLS
    KRAUSE, DS
    ITO, T
    FACKLER, MJ
    SMITH, OM
    COLLECTOR, MI
    SHARKIS, SJ
    MAY, WS
    BLOOD, 1994, 84 (03) : 691 - 701
  • [45] The effect of CD34 count and clonogenic potential of hematopoietic stem cells on engraftment
    Sari, Tamer
    Yuksel, Meltem Kurt
    Topcuoglu, Pervin
    Tol, Meltem
    Ayyildiz, Erol
    Ozcan, Muhit
    Ilhan, Osman
    TRANSFUSION AND APHERESIS SCIENCE, 2010, 43 (03) : 315 - 320
  • [46] Human CD34− Hematopoietic Stem Cells: Basic Features and Clinical Relevance
    Kiyoshi Ando
    International Journal of Hematology, 2002, 75 : 370 - 375
  • [47] CD34 Is a Ligand for Vascular Selectins on Human Hematopoietic Stem/Progenitor Cells
    AbuSamra, Dina Bashir
    BLOOD, 2015, 126 (23)
  • [48] Flow Cytometric Enumeration of Viable CD34(+) Hematopoietic Stem and Progenitor Cells
    Odendahl, M.
    Tonn, T.
    TRANSFUSIONSMEDIZIN, 2012, 2 (03) : 145 - 152
  • [49] EXPRESSION OF THE CD34 GENE IN VASCULAR ENDOTHELIAL-CELLS
    FINA, L
    MOLGAARD, HV
    ROBERTSON, D
    BRADLEY, NJ
    MONAGHAN, P
    DELIA, D
    SUTHERLAND, DR
    BAKER, MA
    GREAVES, MF
    BLOOD, 1990, 75 (12) : 2417 - 2426
  • [50] Identification of Gene Expression-Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes
    Pellagatti, Andrea
    Benner, Axel
    Mills, Ken I.
    Cazzola, Mario
    Giagounidis, Aristoteles
    Perry, Janet
    Malcovati, Luca
    Della Porta, Matteo G.
    Jadersten, Martin
    Verma, Amit
    McDonald, Emma-Jane
    Killick, Sally
    Hellstrom-Lindberg, Eva
    Bullinger, Lars
    Wainscoat, James S.
    Boultwood, Jacqueline
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (28) : 3557 - 3564